PSI CRO has launched SYNETIC, an AI-powered semantic knowledge platform designed to help sponsors identify clinical trial sites, reduce startup delays, and predict sites that may fail to enrol patients.

Underperforming sites remain a major challenge in clinical research, with 37% enrolling poorly and 11% failing to enrol any participants, according to Tufts CSDD. SYNETIC is built on data from more than 500,000 institutions and 3 million study sites across 62 countries, providing insights into site capabilities, operational efficiency, and historical enrolment performance.

The platform is integrated into PSI’s INTELIA clinical trial intelligence suite, which combines operational analytics, predictive modelling, and AI-enabled decision support. SYNETIC applies algorithmic ranking, semantic search and predictive analytics to support feasibility assessments and site selection, aiming to reduce delays in study start-up and improve overall enrolment performance.

Kirill Soldatov, head of process improvement at PSI, said: “INTELIA enables pharma and biotech sponsors to see what works and what doesn’t for their trial before it begins. SYNETIC takes this to the next level by eliminating blind spots in site selection and patient enrolment.”

The system delivers multiple features to support trial planning, including instant site intelligence with detailed profiles, AI-driven site scoring based on protocol fit, agentic AI with natural language processing for advanced search, data-driven site matching for targeted outreach, and interactive knowledge graphs that reveal complex relationships between institutions, investigators, and performance metrics.

SYNETIC’s architecture allows PSI teams and sponsors to access real-time insights, improving decision-making during trial start-up and enabling proactive intervention to prevent non-enrolling sites from affecting study timelines.

Founded in 1995, PSI CRO is a Swiss-based global full-service contract research organisation, specialising in oncology, hematology, gastroenterology, autoimmune, infectious diseases, neurology, and other complex therapeutic areas. The company also supports precision medicine, radiopharmaceuticals, and cell and gene therapy studies. PSI employs 3,200 professionals across 58 countries and delivered over 90% of pivotal Phase 2/3 trials on schedule in 2025.